# Our products

Please note that indications and formulations may vary from country to country. Please refer to the respective local product information or Summary of Product Characteristics (SmPC).

| Active ingredient / Technology | Brand name | Indication range* |
| --- | --- | --- |
| Capsaicin | Qutenza® | **EU indication:** Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain. **US indication:** Treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. |
| Fixed-dose combination of Esomeprazole and Naproxen | Vimovo® | In adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient. |
| Lidocaine | Versatis® | **EU and Peru indication:** Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (postherpetic neuralgia, PHN) in adults. **Latin America indication:** Treatment of localised neuropathic pain, including pain associated with a previous herpes zoster infection (postherpetic neuralgia). |
| Zolmitriptan | Zomig® AscoTop® Nasal | **Oral formulations:** In adults aged 18 years and older for acute treatment of migraine headache with or without aura. **Nasal spray:** In adults and adolescents aged 12 years and older for the acute treatment of migraine headache with or without aura, and in adults for the treatment of cluster headache.*** |
| Testosterone undecanoate | Nebido® | Treatment of male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. |
| Esomeprazole | Nexium® | **20 mg; 40 mg gastro-resistant tablets:** **Indicated in adults for:** **Gastroesophageal Reflux Disease (GERD)** - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) **In combination with appropriate antibacterial therapeutic** regimens for the eradication of Helicobacter pylori and: - healing of Helicobacter pylori associated duodenal ulcer - prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers **Patients requiring continued NSAID therapy:** - healing of gastric ulcers associated with NSAID therapy - Prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk **Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. Treatment of Zollinger Ellison Syndrome** **Indicated in adolescents from the age of 12 years for: Gastroesophageal Reflux Disease (GERD)** - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) **In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori** Nexium™ is also available in other dosage forms with slightly varying indications.# |
| Rosuvastatin | Crestor® | **Treatment of hypercholesterolaemia** Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate. **Prevention of cardiovascular events** Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors. |
| Naloxegol | Moventig® Movantik® | **MoventigTM Indication Europe:** MoventigTM is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). **MovantikTM Indication US:** MovantikTM is an opioid antagonist indicated for the treatment of OIC in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation. |
| Glyceryl trinitrate rectal ointment | Rectogesic® 4mg/g | Relief of pain associated with chronic anal fissures. |
| Granisetron transdermal patch | Sancusco® | Prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult. |

*Status: February 2026. If not otherwise mentioned the EU SmPC approved at the time of review is used as a basis. Please note that indications and formulations may vary from country to country. Please refer to the respective local product information or Summary of Product Characteristics (SmPC)

** Indication in UK: Zomig Nasal Spray is indicated for the acute treatment of migraine with or without aura.

# see SmPC for ‘Nexium™ 10 mg gastro-resistant granules for oral suspension, sachet’ and for ‘Nexium™ 40 mg Powder for solution for injection/infusion’

## Overview of medication that contains an opioid mechanism of action

## Our products

We have been striving to provide solutions for patients with large unmet medical needs for over seven decades. If you are a healthcare professional, find out what we have achieved to date by exploring our product portfolio on Grünenthal's local affiliates pages.

Grünenthal product portfolio | Grünenthal